Tag: began-hearing
-
Merck patents on Hepatitis C treatment found valid in Gilead dispute
By Rory Carroll and Andrew Chung SAN JOSE (Reuters) – Merck & Co told a federal jury on Tuesday it was seeking more than $2 billion in damages from rival Gilead Sciences Inc after the jury upheld the validity of two Merck patents in a high-profile dispute over Gilead's blockbuster cure for hepatitis C. After…